CSL Limited Acquires Vifor Pharma Ltd in All-Cash Tender Offer

Novo Nordisk Acquires Forma Therapeutics

September 1, 2022

Pharmaceuticals

Novo Nordisk will acquire Forma Therapeutics in a cash tender offer at $20 per share, valuing the deal at about $1.1 billion. The acquisition is intended to expand Novo Nordisk’s scientific and pipeline presence in sickle cell disease and other rare blood disorders, including Forma’s lead candidate etavopivat.

Novartis to Acquire MorphoSys in $2.9 Billion Deal

February 7, 2024

Pharmaceuticals

Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).

Camlin Fine Sciences Acquires Majority Stake in Vinpai

November 27, 2025

Healthcare Services

Camlin Fine Sciences Limited (CFSL) completed the acquisition of a majority stake in Vinpai, acquiring 78.68% of its share capital (and 84.89% of voting rights) for EUR 3.60 per share from certain significant shareholders. CFSL plans to file a simplified cash tender offer (OPAS) with France’s AMF for the remaining Vinpai shares at the same price and, if conditions are met, pursue a mandatory squeeze-out.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Sobi Acquires CTI BioPharma Corp.

June 26, 2023

Biotechnology

Swedish Orphan Biovitrum AB (Sobi) completed the acquisition of CTI BioPharma Corp. through a cash tender offer and subsequent merger, paying USD 9.10 per share for a transaction valued at up to USD 1.7 billion. CTI, a Seattle-based biopharmaceutical company with the FDA-approved product VONJO and ~144 employees, becomes an indirect wholly owned subsidiary of Sobi and will be delisted from NASDAQ.

Merck to Acquire Verona Pharma for Approximately $10 Billion

July 9, 2025

Pharmaceuticals

Merck, through a subsidiary, entered into a definitive agreement to acquire Verona Pharma in a transaction valued at approximately $10 billion (at $107 per ADS). The acquisition is intended to add Ohtuvayre (ensifentrine) to Merck’s cardio-pulmonary pipeline, following FDA approval for COPD in June 2024.